Barclays PLC Adma Biologics, Inc. Transaction History

Barclays PLC

$377 Billion
Q3 2024

A detailed history of Barclays PLC transactions in Adma Biologics, Inc. stock. As of the latest transaction made, Barclays PLC holds 528,629 shares of ADMA stock, worth $9.2 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

528,629

Previous 528,629 -0.0%

Holding current value

$9.2 Million

Previous $10.6 Million -0.0%

% of portfolio

0.0%

Previous 0.0%

26 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 15, 2024	BUY	$11.21 - $20.03 $3.9 Million - $6.96 Million	347,692 Added 192.16%	528,629 $10.6 Million
Q2 2024 Aug 14, 2024	SELL	$5.98 - $11.18 $556,809 - $1.04 Million	-93,112 Reduced 33.98%	180,937 $2.02 Million
Q1 2024 May 15, 2024	SELL	$4.4 - $6.74 $1.35 Million - $2.07 Million	-306,689 Reduced 52.81%	274,049 $1.81 Million
Q4 2023 Feb 15, 2024	BUY	$3.08 - $4.52 $548,859 - $805,468	178,201 Added 44.27%	580,738 $2.63 Million
Q3 2023 Nov 07, 2023	SELL	$3.47 - $4.61 $36,587 - $48,607	-10,544 Reduced 2.55%	402,537 $1.44 Million
Q2 2023 Aug 03, 2023	SELL	$3.12 - $4.22 $49,820 - $67,384	-15,968 Reduced 3.72%	413,081 $1.52 Million
Q1 2023 May 04, 2023	SELL	$3.01 - $3.87 $107,511 - $138,228	-35,718 Reduced 7.69%	429,049 $1.42 Million
Q4 2022 Feb 13, 2023	SELL	$2.47 - $3.88 $9,754 - $15,322	-3,949 Reduced 0.84%	464,767 $1.8 Million
Q3 2022 Nov 03, 2022	BUY	$2.03 - $2.86 $723,274 - $1.02 Million	356,293 Added 316.92%	468,716 $1.14 Million
Q2 2022 Aug 12, 2022	SELL	$1.43 - $2.2 $6,885 - $10,593	-4,815 Reduced 4.11%	112,423 $222,000
Q4 2021 Feb 14, 2022	SELL	$1.09 - $1.66 $12,768 - $19,445	-11,714 Reduced 9.08%	117,238 $165,000
Q3 2021 Nov 09, 2021	SELL	$1.13 - $1.65 $371,538 - $542,511	-328,795 Reduced 71.83%	128,952 $145,000
Q2 2021 Aug 13, 2021	BUY	$1.51 - $2.07 $430,836 - $590,616	285,322 Added 165.48%	457,747 $733,000
Q1 2021 May 13, 2021	BUY	$1.67 - $2.95 $287,806 - $508,400	172,339 Added 200394.19%	172,425 $303,000
Q4 2020 Feb 11, 2021	SELL	$1.8 - $2.56 $49,950 - $71,040	-27,750 Reduced 99.69%	86 $0
Q3 2020 Nov 12, 2020	SELL	$2.04 - $3.74 $16,709 - $30,634	-8,191 Reduced 22.74%	27,836 $66,000
Q2 2020 Aug 12, 2020	BUY	$2.42 - $3.29 $30,799 - $41,871	12,727 Added 54.62%	36,027 $106,000
Q1 2020 May 13, 2020	SELL	$1.5 - $4.59 $77,100 - $235,926	-51,400 Reduced 68.81%	23,300 $67,000
Q4 2019 Feb 10, 2020	SELL	$3.89 - $5.15 $1.38 Million - $1.82 Million	-353,887 Reduced 82.57%	74,700 $298,000
Q3 2019 Nov 14, 2019	BUY	$3.19 - $5.39 $1.31 Million - $2.22 Million	410,962 Added 2331.7%	428,587 $1.91 Million
Q2 2019 Aug 14, 2019	SELL	$3.52 - $5.24 $133,203 - $198,292	-37,842 Reduced 68.22%	17,625 $68,000
Q1 2019 May 15, 2019	BUY	$2.61 - $4.35 $144,192 - $240,320	55,246 Added 24998.19%	55,467 $211,000
Q4 2018 Feb 14, 2019	SELL	$2.17 - $6.12 $15,257 - $43,029	-7,031 Reduced 96.95%	221 $1,000
Q3 2018 Nov 14, 2018	BUY	$4.39 - $6.85 $25,742 - $40,168	5,864 Added 422.48%	7,252 $45,000
Q2 2018 Aug 14, 2018	SELL	$4.39 - $5.44 $6,642 - $8,230	-1,513 Reduced 52.15%	1,388 $6,000
Q1 2018 May 15, 2018	BUY	$3.21 - $5.21 $9,312 - $15,114	2,901 New	2,901 $13,000

Others Institutions Holding ADMA

# of Institutions

319

Shares Held

184M

Call Options Held

917K

Put Options Held

91.6K

View Full List

About ADMA BIOLOGICS, INC.

Ticker ADMA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 196,356,992
Market Cap $3.42B
Description
ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. It offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primar...

More about ADMA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.

Account